EUCTR2017-003415-19-SK进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Is able to read, understand, and provide written, dated informed consent prior to Screening Visit. Subjects will be deemed likely to comply with study protocol and communicate with study personnel about AEs and other clinically important information.
- •2. Is male or female, between 18 and 80 years of age at Screening Visit.
- •3. Is diagnosed with idiopathic PD that meets UK Parkinson’s Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria and requires treatment with and shows responsiveness to levodopa.
- •4. Has experienced dyskinesia over a period of at least 3 months prior to Screening Visit
- •5. Has stable peak-effect dyskinesia; the dyskinesia should be moderately to completely disabling (MDS-UPDRS, Part IV, item 4.2, rating = 3).
- •6. Has more than one hour of ON” time with troublesome dyskinesia (i.e., at least three 30-minute periods of ON” time with troublesome dyskinesia) during daily waking hours on a 24-hour Hauser diary on each of 2 consecutive days just prior to Visit 2, Week 0 (Baseline Visit).
- •7. Is on a stable levodopa dosing regimen requiring at least 3 dose administrations but no more than 6 dose administrations per day with at least 2 to 3 hour intervals between 2 successive doses of levodopa for at least 30 days prior to Screening Visit, and is expected to continue this levodopa regimen with no changes for the duration of study participation.
- •8. Must be on a stable dosing regimen if taking other anti-parkinsonian medication(s) and is expected to continue this regimen with no changes for the duration of study participation.
- •9. Is willing and able to stop using;
- •Amantadine ER: from at least 4 weeks prior to Visit 2, Week 0 (Baseline Visit) and for the duration of study participation and/or
- •Amantadine IR: from at least 2 weeks prior to Visit 2, Week 0 (Baseline Visit) and for the duration of study participation and/or.
- •Monoamine oxidase inhibitors (MAOi): from at least 4 weeks prior to Visit 2, Week 0 (Baseline Visit) and for the duration of study participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 41
排除标准
- •A potential subject will not be eligible for participation in this study if any of the following criteria are met:
- •Parkinson’s Disease-Specific Criteria:
- •1. Has undergone surgery for the treatment of PD (e.g., pallidotomy, deep brain stimulation, fetal tissue transplantation) or has undergone any other major brain surgery.
- •Criteria related to psychiatric and other neurological disorders:
- •2. Has current diagnosis of Substance Use (including alcohol) Disorder (Abuse or Dependence, as defined by Diagnostic and Statistical Manual, Fifth Edition[DSM-5], with the exception of caffeine and nicotine dependence, at Screening Visit or within 12 months prior to Screening Visit (e.g., acute intoxication with alcohol, hypnotics, analgesics, or antipsychotic drugs).
- •3. Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses such as bipolar disorder or major depressive disorder, or generalized anxiety disorder that are clinically predominant to their PD or have been predominant to their PD at any time within 6 months prior to Screening Visit.
- •4. Has other psychiatric (not including hallucinations due to side effects of dopamine therapy), neurological or behavioral disorders that in the opinion of the investigator may interfere with the conduct or interpretation of the study, including dementia, or subject who is considered violent.
- •5. Has a significant risk for suicidal behavior in the opinion of the investigator during the course of their participation in the study or
- •At Screening Visit: the subject scores yes” on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to a 6-month period prior to Screening Visit; or
- •At Screening Visit: the subject has had one or more suicidal attempts with reference to a 2-year period prior to Screening Visit; or
- •At Baseline Visit: the subject scores yes” on items 4 or 5 in the Suicidal Ideation section of the C SSRS with reference to Screening Visit; or
- •6. Has current seizure disorders (other than febrile seizures in childhood) requiring treatment with anti convulsants.
- •7. Has known serious ongoing symptomatic cerebral disease or cerebrovascular disease or any acute brain trauma requiring treatment with anti-convulsant therapy (if they are not potent/moderate CYP3A4 inhibitors/inducers, they are prohibited only if given for epilepsy/seizures) within 5 years prior to Visit 2, Week 0 (Baseline Visit).
- •8. Has history of exclusively diphasic, OFF state, myoclonic, dystonic, or akathetic dyskinesia without peak dose dyskinesia.
- •Criteria related to other medical conditions:
- •9. Has current evidence of clinically significant hematological, autoimmune, endocrine, cardiovascular, peripheral vascular, renal (e.g., severe kidney failure[creatinine clearance=20mL/min]), severe liver failure, or gastrointestinal disorder(intestinal ischemia, galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption) or other known condition (e.g. porphyria, unstable diabetes mellitus, acute closed-angle glaucoma, myasthenia gravis) that would possibly interfere with the subject’s participation in the study and/or assessments.
- •10. Has any malignant disease or a history of neoplasms treated within the 3 years prior to the Screening Visit, other than carcinoma in situ of the cervix or basal cell carcinoma of the skin.
- •11. Has orthostatic or symptomatic hypotension: a decrease of > 20 mm Hg in SBP and/or > 10 mm Hg in DBP after at least 3 minutes standing compar
研究者
相似试验
进行中（未招募）
不适用
Study of the safety and effectiveness of two doses of investigational study drug EVP-6124 in subjects with Alzheimer’s DiseaseEUCTR2013-002653-30-ITEnVivo Pharmaceuticals, Inc.790
进行中（未招募）
不适用
Efficacy and Safety of REGN727/SAR236553 Versus Placebo in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Their Lipid-Modifying TherapyEUCTR2012-001222-95-NLRegeneron Pharmaceuticals Inc.250
已完成
3 期
Once-A-Day Pregabalin For Partial SeizuresCTRI/2011/08/001976Pfizer Limited264
进行中（未招募）
1 期
Research study to evaluate SEP-4199 (the study drug) for the Treatment of Depressive Episodes in patients with Bipolar I Disorder.EUCTR2018-000103-16-BGSUNOVION PHARMACEUTICALS INC.341
进行中（未招募）
1 期
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabMedDRA version: 19.0Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersAcute coronary syndromeEUCTR2011-005698-21-EEsanofi-aventis Recherche & Développement18,600